Temas de la conferencia
The 12th World Clinical Biomarkers and CDx Summit returns at a crucial time for the entire precision and targeted drug development industry. Spurred on by a number of recent exciting biomarker-driven therapy and CDx approvals by the FDA, including Eli Lilly's Verzenio, J&J's Amivantamab and Takeda's Mobocertinib, the race to market is becoming ever fiercer to deliver the next-generation of safer and more effective therapies for defined patient populations.
La Sociedad Científica
Hanson Wade
Observaciones
Speakers: Aaron Schetter, Senior Director, Regulatory Affairs, Companion Diagnostics, Daiichi Sankyo, Inc., Amy Gorman, Director, Global Commercial Strategy, Precision Medicine, Janssen, Antonio Chambers, Associate Director, Technical Diagnostic Test
Información e inscripción:
https://go.evvnt.com/1145208-2?pid=4832
Ms. Anita Kelemen
CategoríasDiagnóstico de Laboratorio Químico, Medicina General
